SGYP Stock Overview!Watch My Full Video Chart Analysis For Free On Youtube!
You Can Find The Link Below!
SGYP
SGYP Is Setting Up for A Big Move!SGYP seems to be setting up for a big big move. The Squeeze Momentum Indicator has been forming a triangle which is now about to close and the crosses in the indicator have been black for some time meaning that a release of the squeeze should be about to manifest. My guess is that spike will be to the upside, and it could go as high as 3.60$ (90%+ appreciation), which is the 0.382 retracement level of 17's highs and the 1.618 retracement level of this year's highs.
$SGYP potential bullflag formationseems like a pretty clear bullflag to me let me know what you guys thing
SGYP REACHING A POSSIBLE RETRACING AREASGYP is in uptrend on 4h and it has almost completed an AB=CD pattern. It's in a strong resistance area, so i'm expecting a retrace. Possible bearish divergence.
SGYP Previous strong resistance has been broken.
Next level to watch $ 4.20.
Possible long from here for a $ 0.40 - $ 0.60 movement.
DSKX Begins To Rally After The Conference CallShares of DSKX continues to rally from last week after they held a conference call to discuss the recently announced agreement to acquire Radiancy, Inc., a leading developer of consumer medical devices and the Neova® dermatological products.
It appears investors are beginning to notice the financial value this new deal brings and the future outlook of the company, so if you haven't already, I highly encourage you to listen to today's conference call as soon as possible. Much larger company structure overall, significant increase in revenue, assets, cash flow and working capital with a very reputable management team to move the company forward. The fact that the current market cap is only 33M is what really gets me excited. Listen to the call to learn more:
The replay of the conference call can be heard by dialing 1-888-286-8010 in the United States and Canada or +1-617-801-6888 internationally, then referencing the Conference Passcode "56187013" A recording of the call can also be heard on the company website.
In the call, the DS Healthcare Group management team shared their motivations and answered questions relating to the business fundamentals on the Radiancy & Neova® deal, explaining how natural strategy alignment and synergies will lead to significant bottom line contribution.
The call was hosted by Mark Brockelman (CFO), Manny Gonzeles (CCO) and Renee Barch-Niles (CEO) and took place on Thursday, February 25th, 2016, at 8:30 a.m. EST.
-Renee Barch-Niles (CEO), an experienced CPG Executive who drove double-digit year-over-year growth in global food, drug, mass, club and specialty channels for Global companies such as Daymon Worldwide and Emilia Personal Care.
-Mark Brockelman (CFO) who has great experience in mergers and acquisitions, systems integration expertise and highly astute financial acumen. Mr. Brockelman Brockelman served as the Chief Financial Officer for National Dentex Corporation as well as the Senior Vice President/Chief Financial and Administrative Officer of the Miami Dolphins.
-Manny Gonzalez (CCO), a former top (NASDAQ: PG) Procter & Gamble executive managing a team of 7,000 sales representatives in the U.S., who has direct access to every major retailer in the country.
Acquisition Press Release Below:
finance.yahoo.com
For full disclose please visit: www.stockpicksnyc.com
SGYP Bullish Weekly Seed Wave triggers above $4.70 SGYP has a daily bullish bat in progress but I also looked at the weekly and notice the higher market structure lows which is setting up a weekly seed wave on a price breakout through $4.70. This sets the upside targets on a second leg up at $5.28, $5.60 and $6.06 (the 1.27-1.618 fibs). There are many near-term fundamental catalysts: Paulson & Co. adding 3.2 million shares, top line e&s p3 results for placanatide due out possible this week at UBS Healthcare conference, acquisition spec and 18% short interest possible squeeze.
SGYP Daily Bullish Bat Long Set-UpSGYP setting up a daily bullish bat LONG pattern going into May 20th, 2015, conference. Paulson & Co. took a 2 million share long position according to 13-F. Company has two GI drugs in phase 3 pipeline and is open to acquisition as peer Salix was acquired recently. $4.84-$5.24 upside target projections.
